Physician profile
Erika Simon
NPI 1770255317
$2,933.77
in general payments reported to CMS, 2019-2025
20 companies · $1,697 in 2025
The $1,697 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $155 · 2023: $141 · 2024: $941 · 2025: $1,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,778.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,057.87 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $366.65 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $336.32 | 2024-2025 | |
| Lilly USA, LLC | $253.89 | 2022-2025 | Mounjaro |
| Amgen INC. | $248.03 | 2022-2025 | Evenity, Prolia, Krystexxa |
| Exact Sciences Corporation | $142.73 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $101.58 | 2024 | Intellis Adaptivestim |
| Glaxosmithkline, LLC. | $64.77 | 2022-2025 | Shingrix, Trelegy Ellipta, Bexsero |
| Pfizer INC. | $63.91 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.96 | 2022-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $55.51 | 2025 | Capvaxive, Lagevrio, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $41.05 | 2025 | |
| Dynavax Technologies Corporation | $27.20 | 2024-2025 | Heplisav-B |
| Astellas Pharma US INC | $22.57 | 2024 | Veozah |
| Acadia Pharmaceuticals INC | $18.21 | 2025 | Nuplazid |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $18.00 | 2024 | Trintellix |
| Esperion Therapeutics, INC. | $15.33 | 2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.60 | 2024 | Xifaxan, Trulance |
| Teva Pharmaceuticals USA, INC. | $14.56 | 2022 | |
| Vanda Pharmaceuticals INC. | $14.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.